Bourke et al. characterise the novel type I interferon epsilon (IFNε), as the only IFN constitutively expressed throughout the human female reproductive tract (FRT), where it is hormonally regulated and modules IFN dependent FRT immunity. 
Introduction
The female reproductive tract (FRT) mucosa is a unique site of immune regulation as it must be capable of mounting robust responses against pathogenic infections yet maintain tolerance with commensal bacteria, semen and developing pregnancies (Roy and Matzuk, 2011) .
Epithelial cells that line the vagina, cervix and uterus represent the initial barrier against invading pathogens and are important regulators of immunity through specialised antigen presentation function and secretion of mucins, antimicrobial peptides (AMPs), and chemokines that modulate recruitment and activation of the innate and adaptive immune cells (Wira et al., 2010) . The fluctuation of sex hormones in women, primarily estradiol (E2) and progesterone, across the menstrual cycle likely impact immune function in the FRT, although the mechanisms mediating these effects are not comprehensively defined (Wira et al., 2015) . During the progesterone-dominated luteal phase of menstrual cycle when the endometrium is prepared for fertilisation and implantation, immune responses are suppressed and a tolerogenic state is established (Wira et al., 2015) . However, this environment leaves the FRT susceptible to pathogen invasion. For example, medroxyprogesterone acetate treatment increases Chlamydia trachomatis and HSV2 infection susceptibility in mice (Kaushic et al., 2003; Kaushic et al., 2000) . Far less is known about the link between progestins and STI susceptibility in humans, but there are suggestions that some progestin-based contraceptives are linked with increased susceptibility to HIV (Polis et al., 2016; Polis et al., 2014; Ralph et al., 2015) . However, the factors that mediate the hormonal effects on host defence are not known. Antiviral and immunoregulatory cytokines, such as type I interferon (IFNs), are prime candidates.
The type I IFNs are a family of cytokines that include the conventional α and β subtypes, as well as the more recently identified IFNε. All type I IFNs bind IFN-α receptor 1 (IFNAR1) and IFNAR2, activate JAK-STAT signalling and regulate the expression of potentially thousands of IFN regulated genes (IRGs) (Schindler et al., 2007) . The 'effector' proteins induced by IRGs can modulate a wide range of biological responses, including antiviral, cell cycle regulation, survival/apoptosis, immune effector cell activity and chemotaxis. Regarding STIs in the FRT, epithelial cells that line the vaginal, cervical and endometrial mucosa are key sentinels that produce conventional type I IFNs (e.g. α's and β) upon pathogen challenge (Wira et al., 2010) . Now, a "new" and compelling IFN to consider in FRT immunity is IFNε, which we characterised in mouse models to be constitutively expressed in the endometrium and protective against viral and bacterial STIs (Fung et al., 2013) . We determined that murine IFNε was not induced by pathogen recognition receptor (PRR) pathways like conventional type I IFNs, but was hormonally regulated and accordingly, IFNε levels fluctuated in the endometrium across the estrus cycle. Furthermore, we and others found that in in vitro experiments in human cells, IFNε can block HIV replication at several steps of viral replication by induction of antiviral IRGs Tasker et al., 2016) . However, the critical question of the location and regulation of IFNε in the FRT and its functions there, remains unreported.
Since the role of IFNε in regulating protective immunity in the human FRT will be dependent on which tissues and cells express it, we undertook a thorough investigation of the expression of type I, II and III IFNs, their regulators and their effectors across the FRT.
Methods

Participant recruitment and sampling:
We performed a cross-sectional study (ClinicalTrials.gov number: NCT02416154) of healthy, reproductive-aged women with normal menstrual cycles who were free of exogenous hormonal contraceptives. Being free of exogenous steroid hormones and in a defined (follicular vs luteal) phase of menses was central to the study design and therefore laboratory confirmation by ultra-high-performance liquid chromatography tandem mass spectrometry (UPLC/MS/MS) was performed to evaluate serum progesterone, estradiol as well as a panel of synthetic progestins that cover the majority of regionally available contraceptive progestins. The University of Pittsburgh Institutional Review Board and the Monash Health Human Research Ethics Committee both approved this study. All participants were enrolled at the Center for Family Planning Research at MageeWomen's Hospital in Pittsburgh, Pennsylvania and signed informed consent before study participation.
Between August 2015 and August 2016, 44 participants were assessed for study eligibility and 34 women, age 18-35 years, were enrolled. Of the enrolled participants, 17 were in the follicular phase and 16 were in the luteal phase of menstrual cycle; 1 participant was discontinued after enrolment for a positive screening test for Chlamydia trachomatis. Eligible women were healthy, HIV negative, non-pregnant and reported regular menstrual cycles every 21-35 days. Women were excluded if within 30 days of enrolment they: 1) used any hormonal or intrauterine contraceptive methods; 2) underwent any surgical procedure involving the pelvis (including biopsy); 3) were diagnosed with any urogenital tract infection; 4) used any vaginal or systemic antibiotics, oral or vaginal steroids, or any vaginal product or device (including spermicide, microbicide, douche, sex toy, cervical cap, menstrual collection device, diaphragm, or pessary) except tampons and condoms. Women were also excluded if they used depot medroxyprogesterone acetate within 10 months of enrolment, were pregnant or breastfeeding within 60 days of enrolment or had a new sex partner within 90 days of enrolment. Exclusion criteria included having unprotected heterosexual intercourse since last reported menses, having vaginal or anal intercourse within 36 hours prior to the enrolment study visit, having a prior hysterectomy or malignancy of the cervix or uterus, and having any history of immunosuppression, including immunosuppression associated with chronic disease.
Medical, gynaecologic and sexual histories were obtained and screening procedures were conducted including urine pregnancy testing; rapid HIV screening (OraQuick, OraSure Technologies, Bethlehem, PA, USA); collection of genital tract swabs for detection of Neisseria gonorrhoeae, Chlamydia trachomatis (Hologic Inc., San Diego, CA, USA) and rapid testing for Trichomonas vaginalis (OSOM, Sekisui Diagnostics, Lexington, MA, USA).
Participants were enrolled on the same day as screening when all eligibility criteria were met including no vaginal bleeding on exam and being in the follicular (day 3-12) or luteal (10 days prior to anticipated start of menses) phase of their menstrual cycle by self-report. Given the low risk study population, participants with no clinical signs of genital infection were enrolled with pending screening tests and were discontinued post-enrolment if a screening test rendered them ineligible. Final group allocation to phase of menses was based on UPLC/MS/MS serum hormone analysis with follicular phase serum progesterone <1000pg/mL and luteal phase serum progesterone >2000pg/mL.
Five biopsy samples from the genital tract were obtained: two vaginal biopsies from the upper vagina, two cervical biopsies from the squamocolumnar junction, and one endometrial biopsy.
Vaginal and cervical biopsies were obtained with a standard gynaecologic biopsy instrument and each measured approximately 2 x 3 x 2 mm. The endometrial biopsy was obtained using a standard endometrial sampler (Pipelle, Cooper Surgical, Trunbull, CT, USA). The participants were given the option of a cervical aesthetic injection with 10cc of 1% lidocaine solution prior to the endometrial biopsy. If this was elected, it was administered after the vaginal and cervical biopsies were obtained. One of each of the vaginal and cervical biopsies and ½ of the endometrial biopsy sample were each placed in 1ml RNALater and stored at 4 degrees overnight before being transferred to -80 degrees. The second vaginal and cervical biopsies and the remaining ½ of the endometrial biopsy sample were separately placed into histology cassettes and incubated in 10% formalin fixative for 24 hours at room temperature.
The samples were then transferred to 70% EtOH solution at room temperature. Blood samples were also evaluated by UPLC/MS/MS for quantification of estrogens and progestogens as previously described (Achilles et al., 2018 
Cell culture and reagents:
We performed a series of in vitro experiments to determine the response of cells from different digestion with collagenase and DNase I and filtration, as previously described (Fung et al., 2013) . UECs were stimulated on day 3 of culture.
Gene expression analysis:
RNA was extracted from biopsy samples from the cross-sectional studies described above, Table 1 . Expression was calculated using the 2−ΔΔCT method using 18S as endogenous control.
Immunohistochemistry analysis and quantification:
Thin sections (~4µM) were cut for each tissue and adhered onto Superfrost TM Plus glass slides (ThermoFisher, Australia). Sections were dehydrated using a series of 100% xylene, 100%
ethanol, 70% ethanol and MilliQ water solutions. Heat induced antigen retrieval was performed using a 10mM Trizma ® base (Sigma-Aldrich)/1mM EDTA buffer at pH 9.0. Sections were blocked using CAS-block (Invitrogen), for 1 hour at room temperature, then incubated overnight at 4ºC with the following primary antibodies: rabbit anti-human IFNε (Novus Biologicals), used at 0.5µg/mL; mouse anti-human estrogen receptor α (Dako), provided at ready-to-use concentration; and mouse anti-human progesterone receptor (Dako), used at 1.56µg/mL; all diluted in CAS-block. Corresponding isotype controls were rabbit IgG (Vector Laboratories), used at 0.5µg/mL; and mouse IgG1 (Dako), used at 1.56µg/mL; both diluted in CAS-block. Sections were washed with 0.05% Tween-PBS for 15 minutes and incubated with 60µg/mL biotinylated secondary antibodies (anti-rabbit and anti-mouse, Vector Laboratories)
for 1 hour at room temperature. Slides were washed in 0.05% Tween-PBS for 10 minutes, then incubated for 45 minutes with VECTASTAIN Elite ® ABC-HRP Kit, an avidin-biotinylated peroxidase H complex (Vector Laboratories). Slides were washed again for 10 minutes in 0.05% Tween-PBS, and DAB substrate (Dako) was applied for 30 seconds to initiate precipitate formation/colour development via peroxidase activity. Enzyme activity was stopped in distilled water. Coverslips were applied to slides with DPX mounting media (Merck) and allowed to dry overnight. Slides were manually cleaned, scanned at the Monash Histology Platform using the Aperio Scanscope AT Turbo (Leica Biosystems) and analysed using Aperio ImageScope (v12.3.0.5056, Leica Biosystems) with the Aperio Cytoplasm Algorithm (v2, Leica Biosystems). The epithelium, glands, and stroma were delineated using the pen tool and assessed independently of each other for both nuclear and cytoplasmic staining -an H-score was obtained for each to perform statistical analysis.
Statistical analysis:
For Fluidigm analysis, statistically significant gene changes were determined between conditions using linear modelling, employing the Limma Statistical package [18] . A t-test was used, with a 1.5-fold change cut off and Benjamini-Hochberg correction for false discovery.
Gene expression was considered to be significant below a p value <0.05. For all other data, statistical analyses were performed using GraphPad Prism (v5.02, La Jolla, CA, USA). MannWhitney U-tests, Wilcoxon matched pairs signed rank test and one-way ANOVA with Bonferroni's post entry test were used as indicated. Spearman's rank correlation coefficient analysis was used for all correlation analysis.
Results
IFNε is expressed throughout the human FRT and regulated in response to sex hormones exclusively in the endometrium
We obtained matched FRT tissue and blood samples from a cohort of 33 women (17 in the follicular stage of menstrual cycle and 16 in the luteal stage) with strict inclusion and exclusion criteria to minimize potential confounding factors that could modulate FRT environment. The demographic characteristics of the 33 enrolled and eligible participants did not differ by allocated menstrual phase arm and are shown in Table 1 . The range of serum progesterone concentrations for women allocated to the follicular group vs the luteal group were 26-973 pg/mL and 2075-16,793 pg/mL respectively.
To characterise the spatial expression of IFNε in different parts of the FRT, we first analysed its expression using IHC in matched vaginal, ectocervical and endometrial biopsy samples from all participants. We found IFNε to be highly expressed in the stratified squamous epithelium localised to the basal and parabasal layers of the lower FRT (vagina and the ectocervix) ( Figure 1A and B). In the endometrium, strong IFNε staining was detected in both the luminal and glandular epithelium ( Figure 1C) . In a stratified analysis based on menstrual cycle stage of participants, IFNε protein was significantly higher in the endometrium during the luteal phase of cycle compared with the follicular phase (Figure 2A, 2B) . Conversely, there were no changes in IFNε protein expression across cycle stage in the vagina and ectocervix (Supplemental Figure 1) .
When IFNE mRNA was analysed in biopsy samples, there was significantly higher expression in luteal stage of cycle in the endometrium when compared with endometrial follicular stage expression ( Figure 2C ; p<0.01), a finding consistent with the protein expression data above.
There was no change in vaginal and ectocervical IFNE expression between follicular and luteal stages of cycle. Thus, we established that IFNε is highly expressed throughout the human FRT including the basal layer of epithelium in the cervix and vagina. However, despite high constitutive expression of IFN in the lower FRT, hormonal regulation was not observed in these locations, with IFN only regulated in response to sex hormones within the endometrium.
IFNε expression is negatively regulated by PR
Previous studies from our lab indicated that murine IFNε expression was negatively regulated by progesterone (Fung et al., 2013) , but whether such regulation occurs in the human FRT was unknown. We found high expression of progesterone receptor (PR) protein ( Figure 3A ) and transcript ( Figure 3B ) in the endometrium relative to the very low to undetectable expression in the ectocervix and vagina. Further IHC analysis of PR expression across the FRT revealed strong staining of PR in both luminal and glandular endometrial epithelial cells. Furthermore, the significant reduction of PR expression in follicular stage of menstrual cycle seemed to particularly affect the cytoplasmic expression ( Figure 3C and 3D). We also confirmed that the differential expression of PR with hormonal status in the endometrium was reflected in the mRNA levels, which reinforced the epithelial cell intrinsic nature of these differences ( Figure   3E ).
Since these independent measurements of IFNε and PR expression showed a pattern of inverse correlation, we directly characterised this apparent relationship in the cyclic changes in PR with IFNε expression in each sample and observed that IFNε expression in the FRT indeed showed a significant and inverse correlation with PR, a finding that was significant at both the mRNA and protein level (p<0.05; Figure 4A ). Importantly, this effect was specific to PR expression as we found no correlation between IFNE and ESR1, the gene that encodes ERα, in the FRT, despite ESR1 expression showing significantly lower levels in luteal phase of cycle (Supplemental Figure 2) .
To directly investigate this implied inverse regulation of IFNε by PR, we characterised the regulation by progesterone of a luciferase gene construct under the control of the human IFNε promoter in an endometrial epithelial cell line, ECC1s. We found that stimulation with progesterone significantly inhibited expression of human IFNε (p<0.001; Figure 4C ), yet estrogen stimulation had no effect on promoter activity. To further confirm this finding, we cultured primary uterine epithelial cells from four donor biopsies, stimulated them with progesterone and assessed IFNε expression. In this ex vivo model, IFNε expression significantly decreased following 3 hours of stimulation with progesterone (p<0.05; Figure 4D) whereas stimulation with estrogen did not alter IFNε expression. This data demonstrated the direct regulation of huIFNε expression in vitro by progesterone.
IFNε regulates protective/immunoregulatory IRGs in the human FRT
We previously showed that IFNε protects against in vivo (HSV2 and Chlamydia) and in vitro (HIV) infection, which correlated with regulation of effector IRGs (Fung et al., 2013 This study defines that IFNε is hormonally regulated in the human FRT. Surprisingly, this regulation occurs exclusively in the endometrium and not in the vagina or ectocervix. This is consistent with our finding that progesterone responses directly suppress IFNε expression and that PR is also predominantly expressed in the upper FRT. Indeed, there is a substantial and significant inverse correlation between IFNε and PR expression at the mRNA and protein level across the 32 individuals in this study. While we didn't observe hormonal regulation in the lower FRT, IFNε expression in the human ectocervix has been shown to be upregulated upon exposure to semen (Demers et al., 2014; Sharkey et al., 2007) . This upregulation of ectocervical expression of IFNε in response to semen exposure, examined in a cohort of long term HIV-1 highly exposed, seronegative female sex workers, was hypothesised to be an immunomodulatory mechanism within the FRT to reduce risk of acquisition of HIV (Abdulhaqq et al., 2016) . These results together with our data reported here, confirming constitutive IFNε expression not only in the ectocervix but throughout the FRT and that IFNε regulates IFN immunity in FRT epithelium, is consistent with IFNε likely representing an important basal FRT defence against pathogens.
Based on the evidence presented here, IFNε elicits IRG-driven pathophysiological actions in the FRT and therefore modulation of its expression in the FRT could have profound physiological consequences in terms of susceptibility to infection. For example, women on progestin-based contraceptives have been implied to be more susceptible to infection which may be due, at least in part, to reduce IFNε in the FRT. replicates, shown as mean +SD and analysed using Student's T test, ***p<0.001. (C) Primary uterine epithelial cells were isolated from endometrial biopsies (from n=4 donors) and cultured for 3 days prior to stimulation with either 1 or 3 hours with 10 -9 progesterone or 10 -9 estrogen.
IFNE expression was quantified using qPCR and expressed relative to expression of 18S.
Mann-Whitney U test, *p<0.05. 
